Millennium Management
APGE icon

Millennium Management’s Apogee Therapeutics APGE Stock Holding History

Millennium Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,000
Closed -$434K – 6000
2025
Q2 		$434K Buy
+10,000
New +$380K ﹤0.01% 4987

Other funds holding APGE

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Millennium Management's APGE Position: Q1 2026 in Review

Millennium Management reduced its Apogee Therapeutics (APGE) stake by 34% in Q1 2026, selling an estimated $3.5M and leaving 92,592 shares worth $7.79M. The position accounts for ﹤0.01% of the portfolio, ranked #2430.

Millennium Management first reported a position in APGE in Q4 2023 and has held it in 10 quarters since. The position peaked at $17.1M in Q3 2025. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

  • Millennium Management held 92,592 shares of Apogee Therapeutics worth $7.79M as of Q1 2026.
  • Millennium Management sold 48,135 Apogee Therapeutics shares in Q1 2026, an estimated $3.5M.
  • Apogee Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2430 holding.
  • Millennium Management first reported a position in Apogee Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Millennium Management's Apogee Therapeutics position peaked at $17.1M in Q3 2025.
  • 224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.